Ally Bridge Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Ally Bridge Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-474,741	Closed	-$7.56M	–	19
2022 Q4	$7.56M	Buy	+474,741	New	+$7.42M	7.35%	3

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ally Bridge Group's ACAD Position: Q1 2023 in Review

Ally Bridge Group sold out of Acadia Pharmaceuticals (ACAD) in Q1 2023, closing a stake of 474,741 shares — an estimated $7.56M sold.

Ally Bridge Group first reported a position in ACAD in Q4 2022 and held it in 1 quarter. The position peaked at $7.56M in Q4 2022. 233 funds tracked by Wall St. Rank hold ACAD as of Q1 2023.

Ally Bridge Group reported no remaining Acadia Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Ally Bridge Group sold 474,741 Acadia Pharmaceuticals shares in Q1 2023, an estimated $7.56M.
Ally Bridge Group first reported a position in Acadia Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Ally Bridge Group's Acadia Pharmaceuticals position peaked at $7.56M in Q4 2022.
233 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2023.

Based on Ally Bridge Group's 13F filing for Q1 2023, filed 15 May 2023.